Aprepitant and Fosaprepitant Time-on-Target PET (Positron Emission Tomography) Study (0869-183)

NCT01111851 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

16

Enrollment

INDUSTRY

Sponsor class

Conditions

Chemotherapy-Induced Nausea and Vomiting (CINV)

Interventions

DRUG: Fosaprepitant 150 mg
DRUG: Aprepitant 165 mg
DRUG: Aprepitant 250 mg
DRUG: Dexamethasone (12-8-16-16 mg)
DRUG: Dexamethasone (12-8-8-16 mg)
DRUG: Ondansetron
DRUG: MK0999

Sponsor

Merck Sharp & Dohme LLC